Previous 10 | Next 10 |
2024-04-18 16:32:07 ET More on Fate Therapeutics Fate Therapeutics, Inc. (FATE) Q4 2023 Earnings Call Transcript Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks Fate Therapeutics announces pricing of $100M underwritten offering and concurr...
2024-04-10 17:20:42 ET Gainers: Rallybio Corporation ( RLYB ) +42% . Alpine Immune Sciences ( ALPN ) +36% . Vera Therapeutics ( VERA ) +10% . Relay Therapeutics ( RLAY ) +7% . Olema Pharmaceuticals ( OLMA ) +5% . Lose...
SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellu...
2024-03-28 01:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-25 17:15:09 ET Gainers: Stoke Therapeutics ( STOK ) +87% . AnaptysBio ( ANAB ) +8% . Amneal Pharmaceuticals ( AMRX ) +6% . Omega Therapeutics ( OMGA ) +5% . MoneyHero ( MNY ) +5% . Losers: Ocular Therapeutix...
2024-03-19 08:56:58 ET More on Fate Therapeutics Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks Seeking Alpha’s Quant Rating on Fate Therapeutics Historical earnings data for Fate Therapeutics Financial information for Fate...
SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellu...
SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorder...
CIRM Grant Awarded to Support Phase 1 Autoimmunity Study of FT819 CD19-targeted CAR T-cell Program for Systemic Lupus Erythematosus; Study Start-up Ongoing at Multiple Clinical Sites First Patient Treated in Phase 1 Study of FT522 ADR-armed, CD19-targeted CAR NK Cell Program; Dose Escalat...
SUIC Worldwide Holdings Ltd (SUIC) is expected to report for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 uniQure N.V. (QURE) is expected to report $-1.54 for Q4 2023 Albany International Corporation (AIN) is expected to report $0.84 for Q4 2023 I...
News, Short Squeeze, Breakout and More Instantly...
Fate Therapeutics Inc. Company Name:
FATE Stock Symbol:
NASDAQ Market:
Fate Therapeutics Inc. Website:
A look at the top 10 most actives in the United States Conduit Pharmaceuticals Inc. (CDT) rose 40.0% to $0.3361 on volume of 63,970,490 shares Yoshitsu Co. Ltd (TKLF) rose 64.0% to $0.5024 on volume of 62,618,792 shares Silo Pharma Inc. (SILO) rose 91.8% to $2.0522 on volume of 59,055,593...
2024-06-17 07:30:04 ET Piper Sandler analyst issues OVERWEIGHT recommendation for FATE on June 17, 2024 06:03AM ET. The previous analyst recommendation was Neutral. FATE was trading at $3.61 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellula...